Volume-sensitive anion channels mediate swelling-activated inositol and taurine efflux.
C6 glioma cells accumulate the organic osmolyte inositol in response to chronic hypertonic stress. Upon return to isotonic conditions, cell swelling activates a Na(+)-independent passive low-affinity inositol efflux mechanism that is inhibited 80-100% by a number of anion transport blockers, certain lipoxygenase blockers, and various polyunsaturated fatty acids. Taurine efflux is also enhanced by cell swelling. The taurine efflux pathway has characteristics that are identical to those of the inositol efflux mechanism, including kinetics of activation and inactivation, osmotic sensitivity, pharmacological sensitivity, and inhibition by certain Na+ and Cl- substitutes. These results suggest strongly that volume-sensitive inositol and taurine efflux are mediated by a common transport mechanism. The inhibition of the transport pathway by anion transport blockers and unsaturated fatty acids suggests indirectly that efflux of these solutes may be mediated by an anion channel. Whole cell patch clamp measurements in CsCl solutions were used to test this hypothesis. Under hypertonic conditions, C6 cells had an extremely low membrane conductance (approximately 0.02 nS/pF). After cell swelling, however, whole cell anion conductance was activated rapidly to values up to 1.5-2 nS/pF. This conductance was outwardly rectified and selective for anions and was inhibited 80-100% by blockers of swelling-activated inositol and taurine efflux. The relative taurine permeability (i.e., Ptaurine/PCl) of the conductance was 0.20. Isosmotic replacement of raffinose in the external medium with inositol or sorbitol induced a transient inward current, suggesting that Cl- and these polyols compete for common binding sites on the channel. We conclude that a volume-sensitive anion channel mediates the efflux of structurally diverse organic osmolytes such as taurine and inositol from the cell.
Jackson
P S
PS
Department of Medicine, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
Strange
K
K
D000818:Animals; D001692:Biological Transport / Q000187:drug effects / Q000502:physiology; D002460:Cell Line; D018118:Chloride Channels / Q000037:antagonists & inhibitors / Q000502:physiology*; D002712:Chlorides / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000494:pharmacology; D005910:Glioma; D006982:Hypertonic Solutions; D007294:Inositol / Q000378:metabolism*; D007654:Ketoconazole / Q000494:pharmacology; D007700:Kinetics; D008564:Membrane Potentials / Q000187:drug effects; D009579:Nitrobenzoates / Q000494:pharmacology; D009994:Osmolar Concentration; D051381:Rats; D012964:Sodium / Q000378:metabolism; D015222:Sodium Channels / Q000502:physiology*; D013654:Taurine / Q000378:metabolism*; D014316:Tritium; D014407:Tumor Cells, Cultured
D018118:Chloride Channels; D002712:Chlorides; D005230:Fatty Acids, Nonesterified; D006982:Hypertonic Solutions; D009579:Nitrobenzoates; D015222:Sodium Channels; D014316:Tritium; D013654:Taurine; C058176:5-nitro-2-(3-phenylpropylamino)benzoic acid; D007294:Inositol; D012964:Sodium; D007654:Ketoconazole